Daniel C. Beachler, Yingshi Guo, Wiehong Xiao, Robert D. Burk, Howard Minkoff,
Howard D. Strickler, Ross D. Cranston, Dorothy J. Wiley, Lisa P. Jacobson,
Kathleen M. Weber, Joseph B. Margolick, Elizabeth A. Sugar, Susheel Reddy,
Maura L. Gillison, Gypsyamber D'Souza
Downloaded from https://academic.oup.com/jid/article/212/10/1588/2459184 by guest on 24 June 2022
High Oral Human Papillomavirus Type 16 Load
Predicts Long-term Persistence in Individuals With or
at Risk for HIV Infection
BRIEF REPORT
High Oral Human Papillomavirus
Type 16 Load Predicts Long-term
Persistence in Individuals With or at
Risk for HIV Infection
1
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National
Institutes of Health, Bethesda, 2Department of Epidemiology, and 3Department of
Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore,
Maryland; 4Viral Oncology Program, Ohio State University Comprehensive Cancer
Center, Columbus; 5Department of Pediatrics, 6Department of Microbiology and
Immunology, 7Department of Obstetrics, Gynecology, and Women’s Health,
8
Department of Epidemiology, 9Department of Population Health, Albert Einstein
College of Medicine, Bronx, 10Department of Obstetrics and Gynecology,
Maimonides Medical Center, Brooklyn, New York; 11Department of Medicine,
University of Pittsburgh, Pennsylvania; 12School of Nursing, University of California–
Los Angeles; 13Hektoen Institute of Medicine, The CORE Center at John H. Stroger
Jr. Hospital of Cook County, and 14Department of Infectious Disease, Northwestern
University, Chicago, Illinois
The association between oral human papillomavirus 16
(HPV16) DNA load and infection clearance was evaluated
among 88 individuals with oral HPV16 infection who were
identified within a prospective cohort of 1470 HIV-infected
and uninfected individuals. Oral rinse specimens were
collected semiannually for up to 5 years. The oral HPV16
load at the time of the first positive test result was significantly associated with the time to clearance of infection (continuous P trends <.01). Notably, clearance rates by 24 months
were 41% and 94% in the highest and lowest HPV16 load tertiles (P = .03), respectively. High oral HPV16 load warrants
consideration as a biomarker for infection persistence, the
presumed precursor of HPV16-associated oropharyngeal
cancer.
Keywords.
cancer; HIV.
oral HPV; viral load; persistence; oropharyngeal
Received 23 February 2015; accepted 28 April 2015; electronically published 7 May 2015.
Correspondence: Gypsyamber D’Souza, PhD, 615 N Wolfe St, E6132B, Baltimore, MD 21205
(gdsouza2@jhu.edu).
The Journal of Infectious Diseases® 2015;212:1588–91
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases
Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@
oup.com.
DOI: 10.1093/infdis/jiv273
1588
•
JID 2015:212 (15 November)
•
BRIEF REPORT
METHODS
The study population for the Persistent Oral Papillomavirus
Study (POPS) was nested within 2 prospective, multicenter cohort studies of individuals with or at risk for HIV infection in
the United States: the Women’s Interagency HIV Study (WIHS)
and the Multicenter AIDS Cohort Study (MACS) [5]. A total of
1470 enrolled participants were prospectively followed every 6
months for a maximum of 4 years. The study protocol was approved by the MACS/WIHS executive committee and the institutional review board of each participating site. All participants
provided written informed consent.
Oral samples were collected semiannually from all POPS participants by use of a 30-second oral rinse and gargle with Scope
mouthwash [5]. Oral DNA was isolated by use of a magnetic
bead-based automated platform (QIAsymphony SP, Qiagen)
as previously described [10]. HPV DNA of 37 types (including
HPV16) was detected by polymerase chain reaction (PCR) with
PGMY09/11 primer pools that targeted the L1 gene, followed by
type specification with the Roche linear array. Samples positive
for β-globin were considered evaluable.
Included in this analysis were all 88 POPS participants with
at least 1 oral rinse sample positive for HPV16 DNA who also
had 1 or more oral rinse samples collected at visits subsequent
to the visit at which the HPV16-positive sample was obtained.
Downloaded from https://academic.oup.com/jid/article/212/10/1588/2459184 by guest on 24 June 2022
Daniel C. Beachler,1 Yingshi Guo,4 Wiehong Xiao,4 Robert D. Burk,5,6,7
Howard Minkoff,10 Howard D. Strickler,8,9 Ross D. Cranston,11
Dorothy J. Wiley,12 Lisa P. Jacobson,2 Kathleen M. Weber,13
Joseph B. Margolick,4 Elizabeth A. Sugar,3 Susheel Reddy,14
Maura L. Gillison,4 and Gypsyamber D’Souza2
Oral human papillomavirus 16 (HPV16) infection causes >85%
of HPV-positive oropharyngeal cancers [1], the incidence of
which has been increasing over the past several decades in developed countries [2]. Case-control studies estimate oral HPV16
infection to confer a 50-fold increase in the odds of HPV-driven
oropharyngeal cancer [3]. In the United States, oral HPV16 infection is uncommon (1% prevalence) in the general population
[4], and our preliminary natural history studies indicate that a
majority of oral HPV infections clear within 1–2 years [5].
Thus, a single, qualitative, positive test for oral HPV16 infection
may be a poor predictor of disease risk.
The persistence of cervical HPV infection is an established
surrogate for the risk of cervical dysplasia and cancer, and a
high HPV16 load is associated with both the persistence of cervical infection and the risk of cervical dysplasia [6–8]. Oral
high-risk HPV load was significantly associated with 6-month
infection persistence in a short-term natural history study of infection in HIV-infected individuals [9]. Here we evaluate the association between oral HPV16 load and longer-term infection
persistence within a prospective cohort study of individuals
with or at risk for HIV infection [5].
Table 1. Median Oral Human Papillomavirus Type 16 (HPV16)
Load Across Study Characteristics Among the 88 Individuals
With Oral HPV16 Infection in the Persistent Oral Papillomavirus
Study
Characteristics of
Participants
Subjects,
No.
Copies Per
100 000 Cells,
No., Median
P for Higher
HPV Loada
Type of infection
Incident
Prevalent
.03
35
53
3.1
76.6
≤45
45–54
31
35
8.6
74.1
≥55
22
101.0
Age, yb
.02
Current cigarette
smoker
No
.21
37
37.3
51
65.2
Male (MACS)
40
66.5
Female (WIHS)
Ever had a
tonsillectomy
48
34.8
Yes
Sex
.54
No
Yes
.35
62
21
32.3
48.8
5
28571.4
Not sure
Oral sex partners in
past 6 months, no.
0
1
.56
57
48.4
14
15.0
17
88.9
22
17.0
Positive
HIV status, CD4+
T-cell count
66
57.4
Negative
Positive, >500
cells/µL
22
31
17.0
73.8
Positive, 200–499
cells/µL
24
42.8
Positive, ≤ 200
cells/µL
11
547.3
≥2
HIV status
.11
Negative
.22
Abbreviations: HIV, human immunodeficiency virus; MACS, Multicenter AIDS
Cohort Study; WIHS, Women’s Interagency HIV Study.
a
Calculated using the Mann–Whitney test for medians. Variables were
considered as continuous, when possible (ie, age and number of oral sex
partners).
b
RESULTS
Among the 88 HPV16-positive participants included in this
analysis, 53 had oral HPV16 infections that were prevalent at
baseline, and 35 had oral HPV16 infections that were incident.
The study population included 66 HIV-infected individuals
(75.0%) and 22 HIV-uninfected individuals (25.0%). The median and mean (±SD) oral HPV16 load at the first positive visit
With each 10-year increase in age, the HPV16 load significantly increased by
10.6 HPV16 copies per 100 000 cells.
was 50.2 copies per 100 000 cells (interquartile range [IQR],
0.70–435.14) and 39 760 ± 277 694, respectively.
Associations between demographic and behavioral factors and
oral HPV16 load are presented in Table 1. Oral HPV16 loads were
significantly higher among prevalent versus incident HPV16
BRIEF REPORT
•
JID 2015:212 (15 November)
•
1589
Downloaded from https://academic.oup.com/jid/article/212/10/1588/2459184 by guest on 24 June 2022
The HPV16 load in the first positive sample was estimated by
TaqMan quantitative PCR (qPCR) targeted to the HPV16 E6
open reading frame as previously described [9, 11, 12]. Reported
values are the mean of duplicate samples. To account for possible variations in cellularity between oral rinse samples, the
HPV16 load in each sample was standardized by the number
of human epethelial cells in that sample as measured by number
of a single copy human gene (human endogenous retrovirus
ERV-3), as previously described [13], as previously described
[9, 12]. Seventeen of the 88 samples that were positive for
HPV16 by linear array were negative by qPCR. Differences in
sample volume used for linear array (12 µL) and qPCR (2 µL)
likely resulted in different assay sensitivities, as previously reported [12]. We assigned a viral load of 1 copy per 100 000
cells for these 17 samples [12].
The relationship between demographic, behavioral, and
biological characteristics and HPV16 load were evaluated
using Wilcoxon–Mann–Whitney test for medians. In addition,
Poisson regression with robust variance was used to evaluate
predictors of a higher oral HPV16 load. Variables that were statistically significant (P < .05) in bivariable models and variables
considered relevant based on previous literature were included
in the multivariable models [5].
Time to oral HPV16 clearance was defined as the time from
collection of the first HPV16-positive sample to collection of
the first HPV16-negative sample, with tests performed using
the Roche linear array. An alternate definition of time to 2 consecutive HPV16-negative test results was also considered. For
these analyses, oral HPV16 load was evaluated as a continuous
variable and as a categorical variable in tertiles. Clearance rates
were estimated using the Kaplan–Meier method and compared
by the log-rank test. Hazard ratios were estimated by Cox proportional-hazard models. Approximately 20% of the 88 participants had a missing intermittent visit during the 5 years of
follow-up, and we assumed that the HPV test result for the
missing visit was the same as that from the previous visit, as previously described [5]. The association between oral HPV16 load
and clearance was also considered when stratified by sex, HIV
status, and incident/prevalent status of the HPV16 infection,
since these variables were suggested to be effect modifiers for
some risk factors in previous studies [5]. All statistical tests
were 2-sided and considered significant, using an α level of
0.05. Analyses were performed in Stata MP 12.0.
Figure 1. Kaplan–Meier curves for clearance of human papillomavirus
virus type 16 (HPV16), by oral HPV16 infection tertile. *Oral HPV clearance
defined at first visit when oral HPV16 DNA was not detected. ^Tertile ranges: Lowest tertile 1.0–5.9 copies per 100 000 cells; Middle tertile: 6.0–
155.3 copies per 100 000 cells; Highest tertile: >155.3 copies per
100 000 cells. The P-trend was calculated using the log-rank test.
1590
•
JID 2015:212 (15 November)
•
BRIEF REPORT
P < .001). Estimated 12-month clearance rates were 26% (95%
CI, 12%–44%), 67% (95% CI, 50%–82%), and 83% (95% CI,
65%–94%) for the highest, intermediate, and lowest tertiles, respectively. This trend continued: 41% of infections in the highest viral load tertile, compared with 94% in the lowest tertile,
cleared within 24 months (P = .03). After adjustment for
other factors, infections in the highest HPV16 load tertile
were 4 times less likely to clear than infections in the lowest tertile (adjusted hazard ratio, 0.24; 95% CI, .11–.56; Supplementary
Table 2). Results were also similar when defining clearance on
the basis of 2 negative test results (Supplementary Table 1) and
when restricting to the 71 samples that were detectable by qPCR
(continuous Ptrend <.01; Supplementary Table 2). Among the 17
individuals who were HPV16 positive by linear array but negative by qPCR, 14 (82%) had HPV16 infections that cleared within 12 months, which was similar to the clearance rate among
those who had a lower viral load (1.0–6.0 copies per 100 000
cells), from whom 73% had infections that cleared within 12
months. Analysis within subgroups revealed increasing tertile
of oral HPV16 load to be consistently associated with lower
clearance among incident and prevalent infections, among
men and women, and among HIV-infected individuals and
HIV-uninfected individuals (all Ptrend <.05).
DISCUSSION
In this study of the long-term natural history of oral HPV16 infection in higher-risk HIV-infected adults and HIV-uninfected
adults, we observed oral HPV16 load to be strongly associated
with infection persistence, as over half of oral HPV16 infections
in the highest tertile of viral load persisted for at least 24
months. Oral HPV load therefore warrants further investigation
as a biomarker for longer-term persistence and the risk of
HPV16-positive oropharyngeal cancer.
This study supports and helps elucidate previous findings
from oral HPV natural history studies that suggested older
age, prevalent infection, and current cigarette smoking to increase the risk of oral HPV16 persistence [5, 14]. Our study,
along with another from the US-based National Health and Nutrition Examination Survey (NHANES) [12], suggest that these
factors are associated with higher oral HPV16 load. Thus,
we hypothesize that aging and cigarette smoking may lead to
poorer immunological control and greater replication of oral
HPV16 infections, which in turn leads to longer oral HPV16
persistence. We previously suggested that males are also potentially at increased risk of oral HPV persistence, compared with
females [5], but unlike the NHANES analysis [12], we did not
observe a higher oral HPV load in males. However, we should
note that men and women in this study came from different
study populations that represent higher-risk communities and
that most of the men in the study were men who have sex
with men [5].
Downloaded from https://academic.oup.com/jid/article/212/10/1588/2459184 by guest on 24 June 2022
infections (P = .03) and among older individuals (Ptrend =.02).
With each 10-year increase in age, the HPV16 load significantly
increased by 10.6 HPV16 copies per 100 000 cells. In multivariable analysis, prevalent infection status and older age remained
significantly associated with oral HPV16 load above the median
(Supplementary Table 1). Other factors that were nonsignificantly associated with a higher oral HPV16 load in multivariable analysis included HIV positivity (adjusted prevalence
ratio, 1.64; 95% confidence interval [CI], .91–2.94) and current
cigarette use (adjusted prevalence ratio, 1.50; 95% CI, .98–2.28;
Supplementary Table 1).
Among the 88 individuals in this analysis, 57 (65%) had ≥7
follow-up visits. The median number of visits was 8 (IQR, 5–9
visits). The median follow-up time for participants with oral
HPV16 infections in this study was 35.7 months (IQR, 17.4–
48.5 months; 42.3 months for prevalent infections, and 25.0
months for incident infections). Sixty-three of the 88 infections
were observed to clear at any point during the 5 years of observation. The 12-month clearance rate for all HPV16 infections
was estimated to be 57% (95% CI, 47%–68%), with a higher
clearance rate for incident than prevalent infections (77% vs
44%, respectively; P = .01). When clearance was defined by 2
consecutive negative test results, the 12-month clearance rate
declined to 45% (95% CI, 35%–57%).
The Oral HPV16 load for the first specimen that tested positive was significantly associated with the time to clearance of
infection (continuous Ptrend <.01). Kaplan–Meier curves for
clearance, stratified by oral HPV16 infection tertile, are shown
in Figure 1. Clearance rates were significantly higher for oral
HPV16 infections in the lower viral load tertiles (log-rank
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org). Supplementary materials consist of
data provided by the author that are published to benefit the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.
Notes
Acknowledgments. The Multicenter AIDS Cohort Study (MACS) centers
in the Persistent Oral Papillomavirus Study (POPS) are funded by
U01-AI35042 (Johns Hopkins University–Margolick), U01-AI35039
(Northwestern University–Wolinsky), and U01-AI35041 (University of
Pittsburgh–Rinaldo). The MACS DMAC at Johns Hopkins University
is funded by UM1-AI35043 (Jacobson). MACS data collection is also
supported by UL1-TR000424 (JHU CTSA). The Women’s Interagency
HIV Study (WIHS) centers in the POPS are funded by U01-AI-031834
(Brooklyn–Minkoff and Gustafson), U01-AI-034993 (Chicago–Cohen),
and U01-AI-034993 (Washington–Young). The WIHS DMAC is funded
by U01-AI-042590 (Gange and Golub).
Financial support. This work was supported by the National Institute
of Dental and Craniofacial Research (R01 DE021395 and related supplement to G. D. [ principal investigator]), the National Institute of Allergy
and Infectious Disease (U01-A1-35043), and the National Cancer Institute
(T32 CA CA009314 and cancer prevention fellowship to D. C. B.).
Potential conflicts of interest. G. D., R. D. C., and D. J. W. have/had
research support from Merck. D. J. W. is a member of the speakers bureau
for Merck. M. L. G. has been a consultant for Merck and GSK. R. D. C. also
reports institutional grant funding and royalties from UptoDate (on HPVrelated topics). All other authors report no potential conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
References
1. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467–75.
2. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus
and rising oropharyngeal cancer incidence in the United States. J Clin
Oncol 2011; 29:4294–301.
3. Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for
human papillomavirus type 16-positive and human papillomavirus type
16-negative head and neck cancers. J Natl Cancer Inst 2008;
100:407–20.
4. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 2012; 307:693–703.
5. Beachler DC, Sugar EA, Margolick JB, et al. Risk factors for oral HPV
infection acquisition and clearance among HIV-infected and HIVuninfected adults. Am J Epidemiol 2015; 181:40–53.
6. Gravitt PE, Kovacic MB, Herrero R, et al. High load for most high risk
human papillomavirus genotypes is associated with prevalent cervical
cancer precursors but only HPV16 load predicts the development of
incident disease. Int J Cancer 2007; 121:2787–93.
7. Xi LF, Hughes JP, Castle PE, et al. Viral load in the natural history of
human papillomavirus type 16 infection: a nested case-control study.
J Infect Dis 2011; 203:1425–33.
8. Fontaine J, Hankins C, Money D, et al. Human papillomavirus type 16
(HPV-16) viral load and persistence of HPV-16 infection in women infected or at risk for HIV. J Clin Virol 2008; 43:307–12.
9. Fakhry C, Sugar E, D’Souza G, Gillison M. Two-week versus six-month
sampling interval in a short-term natural history study of oral HPV infection in an HIV-positive cohort. PLoS One 2010; 5:e11918.
10. Broutian TR, He X, Gillison ML. Automated high throughput DNA isolation for detection of human papillomavirus in oral rinse samples.
J Clin Virol 2011; 50:270–5.
11. Gravitt PE, Burk RD, Lorincz A, et al. A comparison between real-time
polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003;
12:477–84.
12. Chaturvedi AK, Graubard BI, Pickard RK, Xiao W, Gillison ML. Highrisk oral HPV load in the US population, NHANES 2009–2010. J Infect
Dis 2014; 210:441–7.
13. Yuan CC, Miley W, Waters D. A quantification of human cells using an
ERV-3 real time PCR assay. J Virol Methods 2001; 91:109–17.
14. Pierce Campbell CM, Kreimer AR, Lin HY, et al. Long-term persistence
of oral human papillomavirus type 16: the HPV infection in men (HIM)
study. Cancer Prev Res (Phila) 2015; 8:190–6.
15. Fakhry C, Rosenthal B, Clark DP, Gillison ML. Associations between
oral HPV16 infection and cytopathology: evaluation of an oropharyngeal “Pap-test equivalent” in high-risk populations. Cancer Prev Res
(Phila) 2011; 4:1378–84.
BRIEF REPORT
•
JID 2015:212 (15 November)
•
1591
Downloaded from https://academic.oup.com/jid/article/212/10/1588/2459184 by guest on 24 June 2022
While a majority of the study participants with a higher oral
HPV16 load had HPV16 infections that persisted for multiple
years, no participants in this study received a diagnosis of oropharyngeal cancer. Preliminary studies of the oral region have
been unable to identify an HPV-positive precancerous lesion,
limiting the potential for developing screening modalities
[15]. At the same time, this lack of identifiable oropharyngeal
precancerous lesions increases the need for biomarkers capable
of identifying HPV infections that are most likely to progress to
cancer. The relatively low incidence of HPV-positive oropharyngeal cancer (approximately 4 cases per 100 000) [2] suggests
that very sensitive and specific markers would be needed for any
potential screening modality to be beneficial. So while a high
viral load appears to be a considerably better predictor of oral
HPV16 persistence than oral HPV16 DNA, viral load alone is
likely too limited in specificity, given that approximately 40% of
the infections with a higher viral load cleared within 2 years.
Given this limited specificity, biomarkers such as HPV16 methylation and HPV16 E6 seropositivity should be further evaluated
to potentially complement oral HPV16 load.
In summary, a higher oral HPV16 load is strongly associated
with multiyear oral HPV16 persistence in a population of individuals with or at risk for HIV infection. While this is the first
long-term study to evaluate oral HPV16 load and oral HPV16
persistence, this study is limited by a 1-time viral load measurement, a limited number of oral HPV16 infections, and a lack of
assessment for oral precancerous lesions. Further investigation is
necessary to better understand the role of the oral HPV16 load in
the natural history of oral HPV infection and the risk of clinical
progression, particularly in HIV-uninfected individuals.